THE ITALIAN REGIONAL ACCESS OF NEW CANCER DRUGS: AN EXAMPLE IN FOUR REGIONS

被引：0
|
作者：
Visentin, E. [1 ]
Heiman, F. [1 ]
Ripellino, C. [1 ]
机构：
[1] IMS Hlth Informat Solut Med Res Srl, Milan, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1296
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN277
引用
下载
收藏
页码：A479 / A479
页数：1
相关论文
共 50 条
  • [31] Advancing early access policies for innovative cancer drugs: a scoping review and explorative analysis in the Italian setting
    d'Errico, Margherita
    Giannarelli, Diana
    d'Angela, Daniela
    Pinto, Carmine
    Polistena, Barbara
    Spandonaro, Federico
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2024, 17 (01)
  • [32] The new regional Italian cuisine cookbook
    Sutton, Judith
    LIBRARY JOURNAL, 2008, 133 (09) : 120 - 120
  • [33] City repair in the new regions on the example of Thueringen
    Schleiff, Heinrich
    DENKMALPFLEGE, 2008, 66 (02): : 126 - 137
  • [34] Faster access to Cancer Drugs Fund
    Tanday, Sanjay
    LANCET ONCOLOGY, 2012, 13 (06): : E234 - E234
  • [35] Inequalities in access to renal cancer drugs
    Fricker, Janet
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (08) : 1226 - 1226
  • [36] International inequities in access to cancer drugs
    不详
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (06) : 781 - 782
  • [37] SINGLE POINT OF ACCESS CLINIC (SPOAC): A NEW REGIONAL LUNG CANCER PATHWAY IN NEW ZEALAND
    Dawkins, P.
    McWilliams, J.
    Sullivan, R.
    THORAX, 2016, 71 : A127 - A127
  • [38] Current Cancer profiles of the Italian regions - Introduction
    Micheli, Andrea
    Francisci, Silvia
    Baili, Paolo
    De Angelis, Roberta
    TUMORI, 2007, 93 (04)
  • [39] Potential of German claims data to characterize utilization of new cancer drugs: the example of crizotinib
    Schwarz, Sarina
    Oppelt, Katja A.
    Heinig, Miriam
    Haug, Ulrike
    FUTURE ONCOLOGY, 2021, 17 (18) : 2305 - 2313
  • [40] Limited access to new drugs in Spain
    Paulino, J
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 562 - 562
12345